A Double-Blinded Randomized Study Investigating a Possible Anti-Inflammatory Effect of Saxagliptin versus Placebo as Add-On Therapy in Patients with Both Type 2 Diabetes And Stable Coronary Artery Disease

Table 2

Glucometabolic variables according to the randomized groups at baseline and after 3 months. Median (25, 75 percentiles) is given.

Parameter	Baseline		3 months		Δp
	Saxagliptin ()	Placebo ()	Saxagliptin ()	Placebo ()
HbA1c (%)	7.5 (7.1, 8.3)	7.3 (6.8, 7.7)	6.9 (6.7, 7.4)	7.2 (6.9, 7.7)	0.017
Glucose (mmol/L)	8.2 (7.7, 9.7)	8.5 (7.4, 10.6)	7.2 (6.5, 10.0)	8.5 (7.7, 10.4)	0.329
Insulin (pmol/L)	72 (55, 139)	60 (43, 104)	58 (52, 116)	71 (38, 119)	0.818
C-peptide (pmol/L)	1090 (810, 1573)	1025 (767, 1345)	897 (758, 1599)	887 (744, 1649)	0.818

 refers to intragroup change in the saxagliptin group, ; Δp refers to difference in changes from baseline to 3 months between the groups.